Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Biotechnology

Healthcare
$9.38 +0.00%

+$0.00 today

Market cap
$622.71M
Beta
-0.53
P/E (TTM)
-8.8
EPS (TTM)
-$2.59
52W Low $8.48High $24.25

Volume 1.30M

Average 0.54M

BCAX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Bicara Therapeutics Inc. Common StockNASDAQ: BCAX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $47.5M rose 38.4% year over year, ahead of the +29.3% change in trailing-twelve-month research & development. Sequentially, it rose 44.0% from the prior quarter. Over 3 fiscal years it compounded at +58.7% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +38.4% holds above the trailing-twelve-month pace of +29.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$47.5M+44.0% QoQ
Last fiscal yearDec 2025
$125.1M+96.6% YoY
LTMMar 2026
$111.11M+29.3% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+38.4%——
1 year+96.6%——
3-year CAGR+58.7%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
125.1M USD
Year-over-year change
+96.6%
3-year CAGR
+58.7%

Research & Development vs competitors

How BCAX compares with its peers on the latest reported figures

  • BCAX's LTM Mar 2026 research & development of $111.11M is the 4th highest of the 6 companies compared; the peer median is $135.36M.
  • Its year-over-year change of +29.3% is the 3rd highest of 6, against a peer median of +22.7%.
  • Over three fiscal years its annual growth of +58.7% compares with a peer median of +26.8%.
BCAX Competitors Peer median
Research & Development for BCAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M +22.3%+26.8%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$145.36M +345.0%+69.4%1223.2%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
BCAXBicara Therapeutics Inc. Common StockLTM Mar 2026$111.11M +29.3%+58.7%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$56.29M +22.7%+23.1%—
CNTXContext Therapeutics Inc.LTM Mar 2026$35.41M +46.4%+65.0%—
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding BCAX) $135.36M+22.7%+26.8%654.7%

Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development31.31M30.62M63.62M125.1M
Selling, General & Admin6.34M9.27M18.77M30.51M
Operating Expenses37.66M39.89M82.39M155.6M
Depreciation & Amortization10K19K56K105K
EBITDA(37.72M)(51.96M)(67.75M)(137.63M)
EBITDA Margin————
Operating Income(37.66M)(39.89M)(82.39M)(155.6M)
Operating Margin————
Interest Income4K1.31M14.58M17.87M
Interest Expense112K000
Other Income / Expenses(188K)(12.09M)14.58M17.87M
Income Before Tax(37.84M)(51.98M)(67.81M)(137.73M)
Pre-Tax Margin————
Income Tax Expense1K5K187K217K
Net Income(37.85M)(51.99M)(68M)(137.95M)
Net Margin————
EPS (Basic)(0.73)(1.00)(1.25)(2.52)
EPS (Diluted)(0.73)(1.00)(1.25)(2.52)
Weighted Avg Shares51.76M51.76M54.42M54.68M
Weighted Avg Shares (Diluted)51.76M51.76M54.42M54.68M

Bicara Therapeutics Inc. Common Stock

NASDAQ:BCAX

Intrinsic Alpha fair value

Locked

Current Price

$9.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.